Holen Sie sich die Stockscreener-App
2.525
4.15%
-0.125
Handel nachbörslich:
2.50
-0.025
-0.99%
Schlusskurs vom Vortag:
$2.65
Offen:
$2.58
24-Stunden-Volumen:
44,466
Relative Volume:
0.79
Marktkapitalisierung:
$6.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.56M
KGV:
-0.2596
EPS:
-9.7281
Netto-Cashflow:
$-12.24M
1W Leistung:
-2.68%
1M Leistung:
-14.77%
6M Leistung:
-59.59%
1J Leistung:
-57.61%
1-Tages-Spanne:
$2.4732
$2.73
1-Wochen-Bereich:
$2.37
$2.74
52-Wochen-Spanne:
$1.76
$19.63
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.506 | 7.29M | 0 | -13.56M | -12.24M | -9.7281 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical PipelineMarket Buzz Alerts - Newser
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical Pipeline ProgressesViral Momentum Trades - Newser
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock - Investing.com India
Processa Pharmaceuticals president David Young buys $4,588 in shares - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock By Investing.com - Investing.com South Africa
Sian Bigora, Processa CDO, buys $5,341 in stock - Investing.com UK
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock By Investing.com - Investing.com Canada
Processa Pharmaceuticals president David Young buys $4,588 in shares By Investing.com - Investing.com Australia
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock - Investing.com
Processa (NASDAQ: PCSA) strategy chief buys 1,369 shares in open market - Stock Titan
Processa (PCSA) CEO adds 1,843 shares and corrects prior Form 4 - Stock Titan
Processa (PCSA) R&D head buys 1,545 shares at $2.97 in open market - Stock Titan
Processa Pharmaceuticals (NASDAQ: PCSA) CAO purchases 1,583 shares and corrects prior Form 4 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 1,984 shares in Form 4 buy - Stock Titan
Processa (NASDAQ: PCSA) CEO George Ng buys 1,843 shares in open market - Stock Titan
Processa Pharmaceuticals (PCSA) CDO buys 1,971 shares in open-market trade - Stock Titan
What Processa Pharmaceuticals PCSA is doing that separates it from the herd Modest Gains 20260507Viral Momentum Stocks - Newser
Processa Pharmaceuticals (PCSA) holder CVI reports 200,000-share stake, 7.0% - Stock Titan
TradingKey - TradingKey
The valuation case for Processa Pharmaceuticals (PCSA) that is hard to ignore (+4.36%) 2026-05-08Viral Momentum Trades - Newser
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Processa Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Guy Wendy - Moomoo
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lin Patrick - Moomoo
2025 Executive Compensation, Ownership, and Governance Overview for Heatwurx, Inc. (Now Based in Vero Beach, FL) - Minichart
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CFO Skibsted buys $5,891 in stock By Investing.com - Investing.com Australia
Processa Pharmaceuticals CFO Skibsted buys $5,891 in stock - Investing.com
Processa Pharma strategy chief Lin buys $4,064 in stock By Investing.com - Investing.com India
Processa Pharma strategy chief Lin buys $4,064 in stock - Investing.com
Processa (PCSA) CAO Wendy Guy buys 1,748 shares in open-market trade - Stock Titan
Processa Pharmaceuticals president David Young buys $4,589 in shares By Investing.com - Investing.com Australia
Processa Pharmaceuticals CEO George Ng buys $5,471 in company stock By Investing.com - Investing.com India
Processa Pharmaceuticals president David Young buys $4,589 in shares - Investing.com
Processa Pharmaceuticals CEO George Ng buys $5,471 in company stock - Investing.com
David Young of Processa (NASDAQ: PCSA) buys 1,706 shares at $2.69 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 2,190 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) CEO George Ng buys 2,034 shares in open-market trade - Stock Titan
Processa (PCSA) strategy chief buys 1,511 shares at $2.69 - Stock Titan
Processa (NASDAQ: PCSA) CDO adds 1,986 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Ng George Kmoomoo - Moomoo
PCSA (Processa Pharmaceuticals) shares gain nearly 2 percent despite wider than expected Q4 2025 per share loss.Preliminary Results - Newser
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Processa Pharmaceuticals Inc-Aktie (PCSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Young David | Pres. Research & Development |
May 15 '26 |
Buy |
2.97 |
1,545 |
4,589 |
15,345 |
| Lin Patrick | Chief Business - Strategy Off |
May 15 '26 |
Buy |
2.97 |
1,369 |
4,066 |
7,594 |
| Guy Wendy | Chief Administrative Officer |
May 15 '26 |
Buy |
2.97 |
1,583 |
4,702 |
8,011 |
| SKIBSTED RUSSELL | Chief Financial Officer |
May 15 '26 |
Buy |
2.97 |
1,984 |
5,892 |
8,466 |
| Young David | Pres. Research & Development |
Apr 30 '26 |
Buy |
2.69 |
1,706 |
4,589 |
13,813 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Apr 30 '26 |
Buy |
2.69 |
2,190 |
5,891 |
6,498 |
| Ng George K | Chief Executive Officer |
Apr 30 '26 |
Buy |
2.69 |
2,034 |
5,471 |
6,013 |
| Lin Patrick | Chief Business - Strategy Off |
Apr 30 '26 |
Buy |
2.69 |
1,511 |
4,065 |
6,236 |
| Guy Wendy | Chief Administrative Officer |
Apr 30 '26 |
Buy |
2.69 |
1,748 |
4,702 |
6,441 |
| Bigora Sian | Chief Development Officer |
Apr 30 '26 |
Buy |
2.69 |
1,986 |
5,342 |
7,496 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):